Patents Assigned to The U.S.A, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20230019488Abstract: Immunogenic compositions are disclosed that include Neisseria meningitidis microvesicles, such as outer membrane vesicles (OMV) and/or blebs, from PorA?PorB? Neisseria, such as PorA?PorB?ampM? Neisseria meningitidis. These immunogenic compositions are of use to induce an immune response to Neisseria, including Neisseria meningitidis and Neisseria gonorrhea.Type: ApplicationFiled: September 2, 2022Publication date: January 19, 2023Applicant: THE U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventors: Margaret Bash, Kathryn Matthias
-
Publication number: 20230003730Abstract: A viral exposure signature (VES) that can identify early stage, pre-symptomatic hepatocellular carcinoma (HCC) among at-risk patients is described. The VES was developed using serological profiling and synthetic virome technology to identify unique viral peptide epitopes corresponding to 61 viral species. Methods of identifying a subject with early stage (pre-symptomatic) HCC using the VES are described.Type: ApplicationFiled: October 9, 2020Publication date: January 5, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Xin Wei Wang, Jinping Liu, Wei Tang
-
Publication number: 20220380471Abstract: Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VHH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric antigen receptors (CARs) and other antibody conjugates targeted to B7H3 are also described. The single-domain antibodies and conjugates thereof can be used for the diagnosis and treatment of B7H3 expressing solid tumors.Type: ApplicationFiled: October 21, 2020Publication date: December 1, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Ruixue Wang, Brad St. Croix, Dan Li
-
Publication number: 20220339278Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: ApplicationFiled: May 11, 2022Publication date: October 27, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey C. Boyington, Barney S. Graham, John R. Mascola, Hadi M. Yassine, Kizzmekia S. Corbett, Syed M. Moin, Lingshu Wang, Masaru Kanekiyo
-
Publication number: 20220291241Abstract: Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (?Syn) in a biological sample or fraction thereof. These methods include the use of an ?Syn seeding assay.Type: ApplicationFiled: March 30, 2022Publication date: September 15, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Byron Winslow Caughey, Bradley Richard Groveman, Christina Doriana Groveman, Lynne DePuma Raymond, Andrew Gregory Hughson
-
Publication number: 20220249518Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.Type: ApplicationFiled: April 20, 2022Publication date: August 11, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter L. Collins, Matthias Lingemann, Shirin Munir
-
Publication number: 20220193227Abstract: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey I. Cohen, Lesley Pesnicak
-
Publication number: 20220127367Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: ApplicationFiled: January 6, 2022Publication date: April 28, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
-
Publication number: 20220098284Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and methods of using those compositions of matter for the same are disclosed. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.Type: ApplicationFiled: December 16, 2021Publication date: March 31, 2022Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
-
Publication number: 20220089694Abstract: Human monoclonal antibodies that specifically bind Ebola virus glycoprotein with nanomolar affinity are described. The monoclonal antibodies were isolated by bulk sorting of plasmablasts from a human Ebola virus vaccinee and pairing of the immunoglobulin heavy and light chain genes using emulsion PCR. The paired immunoglobulin genes were expressed using Fab yeast display to screen and characterize the antibodies. The Ebola virus-specific monoclonal antibodies can be used, for example, to diagnose and treat Ebola virus infection or Ebola virus disease in a subject.Type: ApplicationFiled: December 19, 2019Publication date: March 24, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Nancy J. Sullivan, John Misasi, Brandon Dekosky, Kendra Elizabeth Leigh
-
Publication number: 20220064324Abstract: Camel single-domain monoclonal antibodies that specifically bind human and mouse mesothelin are described. Chimeric antigen receptor (CAR) T cells and antibody conjugates based on the mesothelin-specific antibodies are also described. The disclosed CAR T cells, mesothelin-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of mesothelin-positive cancers.Type: ApplicationFiled: January 2, 2020Publication date: March 3, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Ira H. Pastan, Jessica D. Hong, Nan Li
-
Publication number: 20220041928Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.Type: ApplicationFiled: July 7, 2021Publication date: February 10, 2022Applicants: INTELLIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, U.S.A , AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Howard Y. BELL, Joshua E. Collins, Paul L.A.M. Corstjens, Sukwan Handali, Hans J. Tanke
-
Publication number: 20220023413Abstract: A recombinant, attenuated mumps virus is described. The recombinant virus is based on the genotype A Jeryl Lynn vaccine strain, but is modified to express genotype G consensus fusion (F) and hemagglutinin-neuraminidase (HN) proteins. The recombinant virus optionally includes a mutation that prevents expression of viral protein V. The recombinant mumps virus can be used as a vaccine to inhibit mumps virus infection and the development of mumps disease.Type: ApplicationFiled: December 12, 2019Publication date: January 27, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Steven A. Rubin, Trent J. Bosma, Christian J. Sauder, Tahir H. Malik
-
Publication number: 20210371542Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.Type: ApplicationFiled: November 7, 2018Publication date: December 2, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Dan Li
-
Publication number: 20210355495Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.Type: ApplicationFiled: June 14, 2021Publication date: November 18, 2021Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Chengyu Liu
-
Publication number: 20210324090Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.Type: ApplicationFiled: June 23, 2021Publication date: October 21, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu, Tai Chi Cheuk
-
Publication number: 20210324074Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.Type: ApplicationFiled: July 11, 2019Publication date: October 21, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
-
Publication number: 20210292428Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.Type: ApplicationFiled: August 6, 2019Publication date: September 23, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Bryan D. Fleming
-
Publication number: 20210290749Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.Type: ApplicationFiled: July 6, 2017Publication date: September 23, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Publication number: 20210270921Abstract: Magnetic resonance methods comprise tractographically establishing a path along a structure in a specimen and finding a distribution of structure radii or cross-sectional areas along the path. Based on the distribution and the path, end-to-end functional characteristics of the structure are estimated. For example, nerve transit times or distributions of transit times can be estimated for a plurality of nervous system locations such as Brodmann areas. Comparison of estimated transit times or distributions thereof between reference values or other values from the same structure can be used to assess specimen health.Type: ApplicationFiled: May 3, 2021Publication date: September 2, 2021Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventor: Peter J. Basser